Cargando…
Circulating C1q/TNF-Related Protein 3, Omentin-1 and NGAL in Obese Patients with Type 2 Diabetes During Insulin Therapy
The aim of the study was to quantify the plasma concentration of omentin-1, neutrophil gelatinase-associated lipocalin (NGAL), and complement C1q tumor necrosis factor-related protein-3 (CTRP3) in obese patients with type 2 diabetes, before introducing insulin therapy, in relation to the plasma expr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617185/ https://www.ncbi.nlm.nih.gov/pubmed/31195747 http://dx.doi.org/10.3390/jcm8060805 |
_version_ | 1783433633605877760 |
---|---|
author | Komosinska-Vassev, Katarzyna Olczyk, Pawel Kuźnik-Trocha, Kornelia Jura-Półtorak, Agnieszka Derkacz, Alicja Purchałka, Marcin Telega, Alicja Olczyk, Krystyna |
author_facet | Komosinska-Vassev, Katarzyna Olczyk, Pawel Kuźnik-Trocha, Kornelia Jura-Półtorak, Agnieszka Derkacz, Alicja Purchałka, Marcin Telega, Alicja Olczyk, Krystyna |
author_sort | Komosinska-Vassev, Katarzyna |
collection | PubMed |
description | The aim of the study was to quantify the plasma concentration of omentin-1, neutrophil gelatinase-associated lipocalin (NGAL), and complement C1q tumor necrosis factor-related protein-3 (CTRP3) in obese patients with type 2 diabetes, before introducing insulin therapy, in relation to the plasma expression profiles of these regulatory molecules in the same patients after a 6-month insulin mixture therapy and in obese controls. Elevated plasma NGAL concentrations were found in type 2 diabetic patients as compared with subjects with metabolically healthy obesity. In turn, a 6-month insulin mixture therapy has shown a marked increase in the plasma concentration of omentine-1 and a significant decrease in plasma CTRP3 concentration in obese patients with type 2 diabetes, in relation to the values found in these patients before the implementation of insulin therapy. Insulin mixture therapy has also proved to be an important factor modifying the plasma profile of NGAL, increasing the concentration of this bioactive molecule in the plasma of patients with type 2 diabetes, after 6 months of its use, in relation to the concentration before treatment. The significant changes in the plasma profile of omentin-1, NGAL and CTRP3 during insulin therapy suggest their potential diagnostic utility in monitoring metabolic changes associated with the introduction of insulin treatment in type 2 diabetic patients. |
format | Online Article Text |
id | pubmed-6617185 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66171852019-07-18 Circulating C1q/TNF-Related Protein 3, Omentin-1 and NGAL in Obese Patients with Type 2 Diabetes During Insulin Therapy Komosinska-Vassev, Katarzyna Olczyk, Pawel Kuźnik-Trocha, Kornelia Jura-Półtorak, Agnieszka Derkacz, Alicja Purchałka, Marcin Telega, Alicja Olczyk, Krystyna J Clin Med Article The aim of the study was to quantify the plasma concentration of omentin-1, neutrophil gelatinase-associated lipocalin (NGAL), and complement C1q tumor necrosis factor-related protein-3 (CTRP3) in obese patients with type 2 diabetes, before introducing insulin therapy, in relation to the plasma expression profiles of these regulatory molecules in the same patients after a 6-month insulin mixture therapy and in obese controls. Elevated plasma NGAL concentrations were found in type 2 diabetic patients as compared with subjects with metabolically healthy obesity. In turn, a 6-month insulin mixture therapy has shown a marked increase in the plasma concentration of omentine-1 and a significant decrease in plasma CTRP3 concentration in obese patients with type 2 diabetes, in relation to the values found in these patients before the implementation of insulin therapy. Insulin mixture therapy has also proved to be an important factor modifying the plasma profile of NGAL, increasing the concentration of this bioactive molecule in the plasma of patients with type 2 diabetes, after 6 months of its use, in relation to the concentration before treatment. The significant changes in the plasma profile of omentin-1, NGAL and CTRP3 during insulin therapy suggest their potential diagnostic utility in monitoring metabolic changes associated with the introduction of insulin treatment in type 2 diabetic patients. MDPI 2019-06-05 /pmc/articles/PMC6617185/ /pubmed/31195747 http://dx.doi.org/10.3390/jcm8060805 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Komosinska-Vassev, Katarzyna Olczyk, Pawel Kuźnik-Trocha, Kornelia Jura-Półtorak, Agnieszka Derkacz, Alicja Purchałka, Marcin Telega, Alicja Olczyk, Krystyna Circulating C1q/TNF-Related Protein 3, Omentin-1 and NGAL in Obese Patients with Type 2 Diabetes During Insulin Therapy |
title | Circulating C1q/TNF-Related Protein 3, Omentin-1 and NGAL in Obese Patients with Type 2 Diabetes During Insulin Therapy |
title_full | Circulating C1q/TNF-Related Protein 3, Omentin-1 and NGAL in Obese Patients with Type 2 Diabetes During Insulin Therapy |
title_fullStr | Circulating C1q/TNF-Related Protein 3, Omentin-1 and NGAL in Obese Patients with Type 2 Diabetes During Insulin Therapy |
title_full_unstemmed | Circulating C1q/TNF-Related Protein 3, Omentin-1 and NGAL in Obese Patients with Type 2 Diabetes During Insulin Therapy |
title_short | Circulating C1q/TNF-Related Protein 3, Omentin-1 and NGAL in Obese Patients with Type 2 Diabetes During Insulin Therapy |
title_sort | circulating c1q/tnf-related protein 3, omentin-1 and ngal in obese patients with type 2 diabetes during insulin therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617185/ https://www.ncbi.nlm.nih.gov/pubmed/31195747 http://dx.doi.org/10.3390/jcm8060805 |
work_keys_str_mv | AT komosinskavassevkatarzyna circulatingc1qtnfrelatedprotein3omentin1andngalinobesepatientswithtype2diabetesduringinsulintherapy AT olczykpawel circulatingc1qtnfrelatedprotein3omentin1andngalinobesepatientswithtype2diabetesduringinsulintherapy AT kuzniktrochakornelia circulatingc1qtnfrelatedprotein3omentin1andngalinobesepatientswithtype2diabetesduringinsulintherapy AT jurapołtorakagnieszka circulatingc1qtnfrelatedprotein3omentin1andngalinobesepatientswithtype2diabetesduringinsulintherapy AT derkaczalicja circulatingc1qtnfrelatedprotein3omentin1andngalinobesepatientswithtype2diabetesduringinsulintherapy AT purchałkamarcin circulatingc1qtnfrelatedprotein3omentin1andngalinobesepatientswithtype2diabetesduringinsulintherapy AT telegaalicja circulatingc1qtnfrelatedprotein3omentin1andngalinobesepatientswithtype2diabetesduringinsulintherapy AT olczykkrystyna circulatingc1qtnfrelatedprotein3omentin1andngalinobesepatientswithtype2diabetesduringinsulintherapy |